EXAS Stock Overview
Provides cancer screening and diagnostic test products in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 6/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Exact Sciences Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$42.25 |
| 52 Week High | US$100.77 |
| 52 Week Low | US$40.62 |
| Beta | 1.26 |
| 11 Month Change | -5.73% |
| 3 Month Change | -38.82% |
| 1 Year Change | -55.01% |
| 33 Year Change | -65.60% |
| 5 Year Change | -64.21% |
| Change since IPO | 186.44% |
Recent News & Updates
Exact Sciences: Still No Reason To Own
Jun 11Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive
Jun 02
Recent updates
Exact Sciences: Still No Reason To Own
Jun 11Revenues Working Against Exact Sciences Corporation's (NASDAQ:EXAS) Share Price Following 27% Dive
Jun 02An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 46% Undervalued
Feb 23Investors Don't See Light At End Of Exact Sciences Corporation's (NASDAQ:EXAS) Tunnel
Jan 08Exact Sciences Corporation (NASDAQ:EXAS) Shares Could Be 42% Below Their Intrinsic Value Estimate
Nov 15Exact Sciences (NASDAQ:EXAS) Is Carrying A Fair Bit Of Debt
Oct 04An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 44% Undervalued
Aug 14Here's Why Exact Sciences (NASDAQ:EXAS) Can Afford Some Debt
Jun 15Calculating The Fair Value Of Exact Sciences Corporation (NASDAQ:EXAS)
Apr 26We Think Exact Sciences (NASDAQ:EXAS) Has A Fair Chunk Of Debt
Feb 23An Intrinsic Calculation For Exact Sciences Corporation (NASDAQ:EXAS) Suggests It's 45% Undervalued
Jan 10Would Exact Sciences (NASDAQ:EXAS) Be Better Off With Less Debt?
Oct 31Exact Sciences: Price Is Yet To Catch Up As Management Draws Profitability Plans
Oct 13Exact Sciences: Negative EPS And Free Cash Flow, More Downside Likely
Aug 15Shareholder Returns
| EXAS | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.8% | -0.7% | 0.04% |
| 1Y | -55.0% | 10.0% | 20.7% |
Return vs Industry: EXAS underperformed the US Biotechs industry which returned 10% over the past year.
Return vs Market: EXAS underperformed the US Market which returned 20.7% over the past year.
Price Volatility
| EXAS volatility | |
|---|---|
| EXAS Average Weekly Movement | 7.5% |
| Biotechs Industry Average Movement | 10.4% |
| Market Average Movement | 5.7% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: EXAS's share price has been volatile over the past 3 months.
Volatility Over Time: EXAS's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 6,550 | Kevin Conroy | www.exactsciences.com |
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.
Exact Sciences Corporation Fundamentals Summary
| EXAS fundamental statistics | |
|---|---|
| Market cap | US$8.21b |
| Earnings (TTM) | -US$240.23m |
| Revenue (TTM) | US$2.53b |
3.1x
P/S Ratio-32.5x
P/E RatioIs EXAS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EXAS income statement (TTM) | |
|---|---|
| Revenue | US$2.53b |
| Cost of Revenue | US$667.48m |
| Gross Profit | US$1.87b |
| Other Expenses | US$2.11b |
| Earnings | -US$240.23m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.30 |
| Gross Margin | 73.67% |
| Net Profit Margin | -9.48% |
| Debt/Equity Ratio | 75.5% |
How did EXAS perform over the long term?
See historical performance and comparison